Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock
Apogee Therapeutics (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the company's stock on April 1st for $466,620, executed under a pre-arranged Rule 10b5-1 plan. This sale is part of a larger pattern of disposals throughout the year, totaling 35,200 shares since January. Despite these insider sales, Apogee Therapeutics currently holds a "Moderate Buy" rating from analysts with an average price target of $110.79.
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options for 4,125 shares and subsequently sold 5,500 common shares in open-market trades at weighted average prices between $84.31 and $85.89. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025, and after the sales, Dambkowski retains 208,398 directly held shares. The sales represent a modest net reduction in his holdings, with a significant portion of his future compensation still tied to the company's equity performance through unvested options.
Apogee Therapeutics (APGE) CMO sells shares worth $466,619
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 5,500 shares of common stock for approximately $466,619 on April 1, 2026. This sale occurred while the stock was trading near its 52-week high, following a significant 161% return over the past year. Dambkowski also exercised options for 4,125 shares on the same day and continues to directly own 208,398 shares, with transactions executed under a Rule 10b5-1 trading plan.
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE
Banque Pictet & Cie SA has initiated a new position in Apogee Therapeutics Inc., purchasing 41,800 shares valued at approximately $3.16 million, representing 0.06% of the company. This investment comes despite recent insider selling, where CEO Michael Henderson and other insiders disposed of shares worth over $140 million, although insiders still retain a substantial 42.77% ownership. Apogee Therapeutics currently holds a consensus "Moderate Buy" rating from analysts with a target price of $110.79, while its stock trades around $84.
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE
SG Americas Securities LLC reduced its stake in Apogee Therapeutics Inc. by 45.4% in the fourth quarter, selling 60,964 shares and retaining 73,262 shares valued at $5.53 million. Despite significant insider selling totaling $140.12 million in the last 90 days, insiders still own 42.77% of the company. Analysts maintain a "Moderate Buy" rating with an average price target of $110.79, while the stock currently trades around $84.
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week High - Here's What Happened
Apogee Therapeutics (NASDAQ:APGE) reached a new 52-week high of $86.93, with its stock trading at $84.87 on Wednesday, April 1, 2026. This surge follows several analyst upgrades to a "Moderate Buy" consensus with an average price target of $110.79. Despite significant insider selling totaling approximately $140.1 million in the last 90 days, institutional ownership remains high at around 79%.
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137
BTIG has reiterated its Buy rating for Apogee Therapeutics (APGE.US) and maintained a target price of $137. This indicates continued confidence from the firm in the company's financial prospects.
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com
BTIG has reiterated a Buy rating and a $137 price target for Apogee Therapeutics (NASDAQ:APGE) after the company presented positive 52-week APEX Part A results. The biotech stock, currently trading at $78.72 with a $5.75 billion market cap, has shown robust performance with a 96% return over the past year. Upcoming data from APEX Part B in Q2 2026 is expected to be a significant catalyst, building on strong clinical data for zumilokibart in atopic dermatitis and recent successful public offerings.
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?
Apogee Therapeutics recently announced positive 52-week Phase 2 trial data for its atopic dermatitis drug, zumilokibart, suggesting potential for infrequent 3- or 6-month dosing. The company also completed a $403 million equity raise, bolstering its balance sheet for future trials. While the market is still processing this news, including insider selling and dilution, the main focus for investors shifts to execution risk and upcoming clinical readouts.
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho
Mizuho has increased its price target for Apogee Therapeutics (NASDAQ:APGE) to $110.00 from $105.00, reiterating an "outperform" rating and suggesting a potential upside of over 40%. This aligns with the average analyst consensus of a "Moderate Buy" with a target of $110.79, although recent insider selling activity by Fairmount Funds and other insiders has been substantial. Apogee Therapeutics, a clinical-stage biotechnology company, is focused on developing novel small molecule therapeutics for autoimmune and inflammatory skin disorders.
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation
Mizuho has initiated coverage of Apogee Therapeutics (APGE) with an "Outperform" rating. The firm set a price target of $80.00 for the company, indicating confidence in its future performance. This initiation suggests a positive outlook from Mizuho regarding Apogee Therapeutics' stock.
Apogee Therapeutics CFO Henderson sells $170k in stock
Jane Henderson, CFO of Apogee Therapeutics (NASDAQ:APGE), sold 2,000 shares of common stock for $170,000 on March 25, 2026, according to an SEC filing. This sale, executed under a Rule 10b5-1 trading plan, occurred near the stock's 52-week high, while the company has recently completed several significant stock offerings to raise capital. Guggenheim also raised its price target for Apogee Therapeutics to $160 from $130, maintaining a Buy rating following positive trial data for zumilokibart.
Insider Sell Alert: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE)
Jane Henderson, CFO of Apogee Therapeutics Inc (APGE), sold 2,000 shares of the company on March 25, 2026, reducing her holdings to 179,371 shares. This sale is part of a larger trend where insiders have sold 28 times with no buys in the past year. The transaction occurred when the stock was trading at $85 per share, giving Apogee Therapeutics a market cap of $5.805 billion.
Apogee Therapeutics (APGE) CFO sells 2,000 shares in planned trade
Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock at $85.00 per share on March 25, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Henderson directly holds 179,371 shares of Apogee common stock.
Fairmount Funds reveals near-10% Apogee Therapeutics (APGE) stake and 60-day lock-up
Fairmount Funds and its principals have reported an updated beneficial ownership stake in Apogee Therapeutics (APGE) just under 10%. The filing details a complex structure of common and non-voting common shares, along with vested options, all subject to a 9.99% beneficial ownership cap. Additionally, Fund II, a Fairmount entity, has entered into a 60-day lock-up agreement, committing not to sell Apogee securities without underwriter consent following the company's recent public offering, and did not participate in purchasing shares in that offering.
Apogee Therapeutics announces $300 million public offering
This article announces that Apogee Therapeutics has initiated a public offering of its common stock and pre-funded warrants, aiming to raise $300 million. The offering includes 8,823,529 shares of common stock at $34 per share and pre-funded warrants for another 882,352 shares at $33.99 per warrant. The company has also granted underwriters a 30-day option to purchase up to an additional 1,455,882 shares.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics, Inc. announced the closing of its underwritten public offering, raising approximately $403 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase additional shares. The company, a clinical-stage biotechnology firm, specializes in developing novel biologics for inflammatory and immunology markets.
Biotech Apogee raises $403M after underwriters buy extra shares
Apogee Therapeutics, Inc. announced the closing of its underwritten public offering, raising approximately $403 million in gross proceeds. The offering involved 5,750,000 common shares priced at $70.00 each, including the full exercise of the underwriters' option to purchase additional shares. This capital raise will support Apogee's work as a clinical-stage biotechnology company focused on novel biologics for inflammatory and immunology markets.
Vanguard disaggregates holdings; Apogee Therapeutics (NASDAQ: APGE) shows 0 shares
Vanguard Group has filed an amended Schedule 13G/A report for Apogee Therapeutics (NASDAQ: APGE), indicating beneficial ownership of 0 shares, representing 0% of the common stock. This change is due to an internal realignment within Vanguard, leading certain subsidiaries to report separately as per SEC Release No. 34-39538. The filing emphasizes that this is a procedural disclosure reflecting a reporting structure change, not an economic transfer or sale of shares.
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis
Apogee Therapeutics shares increased significantly after the company announced positive interim results from its global Phase 2 study of zumilokibart (APG777) for moderate-to-severe atopic dermatitis. The data demonstrated a rapid and deep clinical response, supporting the drug's potential as a best-in-class treatment. The company plans to initiate a Phase 3 study in the first half of 2025.
Apogee Therapeutics raises $403 million in stock offering
Apogee Therapeutics Inc. successfully completed an underwritten public offering, raising approximately $403 million in gross proceeds from the sale of 5.75 million common shares at $70.00 each. The stock is currently trading at a 12% premium to the offering price, reflecting strong investor interest. The clinical-stage biotechnology company, which develops biologics for inflammatory and immunology markets, now holds more cash than debt on its balance sheet.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the closing of its underwritten public offering, including the full exercise of the underwriters' option to purchase additional shares. The offering involved 5,750,000 shares of common stock at $70.00 per share, generating aggregate gross proceeds of approximately $403 million. The company aims to advance novel biologics for inflammatory and immunological markets.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee Therapeutics, Inc. announced the closing of its underwritten public offering, which included the full exercise of the underwriters’ option to purchase additional shares. The offering generated aggregate gross proceeds of approximately $403 million. This capital will support Apogee, a clinical-stage biotechnology company, in advancing its novel biologics for inflammatory and immunological diseases.
Apogee Therapeutics announces $377.4 million public offering of common stock
Apogee Therapeutics announced a public offering of 5,000,000 shares of its common stock at $70.00 per share, with underwriters fully exercising an option for an additional 750,000 shares, resulting in an expected net proceeds of approximately $377.4 million. The company, which already holds more cash than debt and has a strong current ratio, has also recently seen positive Phase II clinical trial results for its drug zumilokibart, leading to varied analyst ratings and price targets.
Apogee Therapeutics announces $377.4 million public offering of common stock
Apogee Therapeutics announced a $377.4 million public offering of 5,000,000 shares of common stock at $70.00 per share, with underwriters exercising their option to purchase an additional 750,000 shares. The company has strong liquidity and aims to close the transaction soon. This follows recent clinical success for its zumilokibart treatment and several analyst rating updates.
[8-K] Apogee Therapeutics, Inc. Reports Material Event
Apogee Therapeutics, Inc. (APGE) has filed an 8-K report detailing an underwriting agreement for the sale of 5,000,000 shares of common stock at $70.00 per share. Underwriters exercised their option for an additional 750,000 shares, bringing the total expected net proceeds to approximately $377.4 million. The offering is anticipated to close on March 26, 2026, and is being conducted under a pre-existing shelf registration statement.
Apogee Therapeutics Prices Upsized Public Equity Offering
Apogee Therapeutics has priced an upsized public equity offering, selling 5.75 million shares at $70.00 each, raising approximately $377.4 million in net proceeds. This move strengthens the company's capital position and financial flexibility for future operations. Although TipRanks' AI Analyst, Spark, rates APGE as Neutral due to accelerating cash burn and widening losses, the offering indicates the company's ability to access equity markets at a premium and supports its ongoing R&D activities.
Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net
Apogee Therapeutics has priced a public offering of 5.75 million shares of common stock at $70 per share, which includes a fully exercised underwriter option for 750,000 additional shares. The company anticipates net proceeds of approximately $377.4 million from the offering, with closing expected on March 26, 2026. The offering is detailed in an underwriting agreement signed on March 24, 2026, aimed at raising capital.
Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering
Apogee Therapeutics (NASDAQ: APGE) has raised approximately $329 million through an offering of 5 million shares of its voting common stock at $70.00 per share, with underwriters having an option to purchase an additional 750,000 shares. The company plans to use these proceeds to fund preclinical studies, clinical trials, manufacturing, commercial readiness, and R&D for its antibody programs, including APG777 for atopic dermatitis, extending its operational runway into the first quarter of 2029. New investors will experience immediate and substantial dilution of $53.36 per share.
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, Inc. announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at $70.00 per share, aiming to raise approximately $350 million. The offering is expected to close on March 26, 2026, with an option for underwriters to purchase additional shares. The company, a clinical-stage biotechnology firm, focuses on advancing novel biologics for inflammatory and immunology markets.
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at $70.00 per share, aiming to raise approximately $350 million. The offering is expected to close on March 26, 2026, and the company has granted underwriters a 30-day option to purchase an additional 750,000 shares. The clinical-stage biotechnology company focuses on advancing novel biologics for inflammatory and immunology markets.
Apogee Therapeutics prices $350 million underwritten public offering at $70.00 per share
Apogee Therapeutics has priced an underwritten public offering of $350 million at $70.00 per share. This announcement follows recent news of positive 52-week data from a Phase 2 trial of its drug Zumilokibart, which demonstrated durable maintenance and deepening of responses in moderate-to-severe atopic dermatitis patients. The company specializes in developing biologics for inflammatory and immunology indications like atopic dermatitis, COPD, and asthma.
Biotech Apogee sells 5 million shares at $70 to raise $350M
Apogee Therapeutics (Nasdaq: APGE) has priced an underwritten public offering of 5 million common shares at $70.00 per share, aiming to raise $350 million in gross proceeds. The offering is expected to close on March 26, 2026, with underwriters having a 30-day option to purchase an additional 750,000 shares. This move continues Apogee's pattern of accessing equity markets for capital, following previous successful offerings.
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, a clinical-stage biotechnology company, announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at $70.00 per share, aiming to raise approximately $350 million. The offering is expected to close on March 26, 2026, with an option for underwriters to purchase an additional 750,000 shares. The company specializes in developing novel biologics for inflammatory and immunology markets.
Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart Data - Has The Bull Case Changed?
Apogee Therapeutics reported positive 52-week maintenance data for zumilokibart, showing durable responses in atopic dermatitis and potential for less frequent dosing. Despite this positive clinical data, the company's stock fell 7.1%, raising questions about its investment narrative given it's a pre-revenue company with large losses and valuation concerns. The next key catalyst is the Part B readout in Q2 2026.
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
Apogee Therapeutics, Inc. (Nasdaq: APGE) priced its underwritten public offering of 5,000,000 shares of common stock at $70.00 per share, aiming to raise approximately $350 million in gross proceeds. The clinical-stage biotechnology company focuses on advancing novel biologics for inflammatory and immunology markets. The offering is expected to close on March 26, 2026, with an option granted to underwriters for an additional 750,000 shares.
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00
Canaccord Genuity Group raised its price target for Apogee Therapeutics (NASDAQ:APGE) to $130.00 from $89.00, citing positive Phase 2 data and implying a significant upside. Despite this and other analyst upgrades, the company's planned $300M public offering and recent insider selling present near-term dilution risks. Apogee Therapeutics' stock has recently traded down, although it has shown a generally upward trend in its moving averages.
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics (APGE) stock surged 20% after reporting positive 52-week maintenance data from its mid-stage study of zumilokibart (APG777) for moderate-to-severe atopic dermatitis. The drug demonstrated sustained efficacy with both three- and six-month maintenance dosing, showing continued improvement over time and a favorable safety profile. The company plans to initiate Phase III development in late 2026, with a potential commercial launch in 2029.
Apogee Therapeutics stock price target raised to $160 by Guggenheim on trial data
Guggenheim raised its price target for Apogee Therapeutics (NASDAQ:APGE) to $160 from $130, maintaining a Buy rating, following positive Phase 2 Part A maintenance data for its drug zumilokibart (APG777). The data indicated responses comparable to existing treatments, leading Guggenheim to double its peak sales forecast for zumilokibart in atopic dermatitis to $5.2 billion. Other analysts from Truist Securities, Mizuho, BofA Securities, and Jefferies also reacted positively to recent clinical trial results and a $300 million public stock offering.
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics, Inc. has announced a proposed $300 million underwritten public offering of its common stock, with an additional option for underwriters to purchase up to $45 million more shares. The biotechnology company plans to use the net proceeds, along with existing funds, to advance its antibody programs, fund preclinical studies, clinical trials, manufacturing, and other general corporate purposes. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers.
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced a proposed underwritten public offering of $300 million of its common stock, with an option for underwriters to purchase an additional $45 million. The biotechnology company plans to use the proceeds, alongside existing funds, to advance its antibody programs through preclinical studies, clinical trials, and manufacturing, as well as for general corporate purposes. Apogee specializes in developing novel biologics for inflammatory and immunology markets, with its leading program, Zumilokibart (APG777), targeting Atopic Dermatitis, asthma, and Eosinophilic Esophagitis.
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics, Inc. has announced a proposed underwritten public offering valued at $300 million. This news, reported by Reuters, indicates a significant financial move for the company. The brief article, published by Refinitiv on TradingView, signals potential growth or operational changes for Apogee Therapeutics.
Apogee seeks $300M to fund clinical trials and manufacturing
Apogee Therapeutics (Nasdaq: APGE) announced a proposed underwritten public offering of $300 million of common stock, with an option for underwriters to purchase an additional $45 million. The net proceeds are intended to fund preclinical and clinical programs, manufacturing, and commercial readiness activities, among other general corporate purposes. Following the news, APGE's stock declined by 7.33%, reflecting market concerns about potential dilution for existing shareholders.
Wedbush Raises Apogee Therapeutics Price Target Amidst Promising Drug Data
Wedbush has increased its price target for Apogee Therapeutics (APGE) to $95 following positive advancements in its Phase 2 study for eczema treatment, leading to a 17.98% rise in stock. Despite reporting wider net losses for FY25, Apogee holds a strong cash reserve of $902.9M, projected to sustain operations through 2028. Analysts remain cautiously optimistic, emphasizing the potential of its therapeutic pipeline amidst financial challenges.
Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
Apogee Therapeutics' stock rallied after disclosing positive 52-week data from its Phase 2 APEX trial for zumilokibart (APG777), a potential treatment for moderate-to-severe atopic dermatitis. The data showed durable efficacy with long dosing intervals and strong IL-13 inhibition. The company plans to initiate Phase 3 trials later this year, with a commercial launch anticipated in 2029.
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis (APGE:NASDAQ)
Apogee Therapeutics announced positive 52-week maintenance data from its phase 2 APEX clinical trial for zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis. Zumilokibart is an anti-IL-13 antibody. The news led to a pre-market rally in Apogee Therapeutics' shares.
Apogee Therapeutics posts positive 52-week Phase 2 APEX Part A results for zumilokibart
Apogee Therapeutics announced positive 52-week Phase 2 Part A maintenance data for its drug zumilokibart (APGE), showing durable and deepening responses in patients. The data highlighted significant EASI-75 and vIGA 0/1 maintenance rates, along with substantial itch reduction, and a safety profile consistent with its class. The company anticipates a Part B 16-week readout in Q2 2026 and aims for Phase 3 initiation in the second half of 2026, targeting a potential 2029 launch.
Apogee Therapeutics (Nasdaq: APGE) reports durable 52-week AD results for zumilokibart
Apogee Therapeutics announced positive 52-week data from Part A of its Phase 2 APEX trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, demonstrating durable disease control with infrequent dosing (every 3- and 6-months). The drug showed deepening responses in lesion and itch endpoints with a safety profile consistent with its class. Apogee plans to initiate Phase 3 trials in the second half of 2026, aiming for a potential commercial launch in 2029 in the estimated $50 billion atopic dermatitis market.
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics announced positive 52-week data from Part A of its Phase 2 APEX clinical trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, showing durable maintenance and deepening of responses with every 3- and 6-month dosing. The drug was well-tolerated, demonstrating a potentially best-in-class profile with significantly less frequent dosing compared to current standard of care. These results support the planned initiation of Phase 3 trials in the second half of 2026, targeting a commercial launch in 2029.
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
Apogee Therapeutics, a clinical-stage biotechnology company, announced a proposed underwritten public offering of $300 million of its common stock, with an option for underwriters to purchase an additional $45 million. The company plans to use the net proceeds to fund preclinical studies, clinical trials, manufacturing, and commercial readiness for its antibody programs, as well as for general corporate purposes. The offering is subject to market conditions, and Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers.
